Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142923 | 0.73 | CDK1 (0.40) | DYRK1ACYP3A4BLM | |
| SCHEMBL536980 | 0.69 | DPP4 (0.34) | — | |
| SCHEMBL8884479 | 0.65 | — | — | |
| SCHEMBL536868 | 0.65 | — | — | |
| SCHEMBL6712707 | 0.60 | — | — | |
| SCHEMBL536971 | 0.60 | LRRK2 (0.31) | CHEK1DAPK3CSF1RRETFGFR1 | |
| SCHEMBL8886045 | 0.59 | CDK1 (0.43) | — | |
| SCHEMBL17824203 | 0.59 | CDK1 (0.33) | — | |
| SCHEMBL7587289 | 0.58 | CHEK1 (0.39) | CHEK1AURKADAPK3JAK2ABL1 | |
| Hydrochloric Acid SCHEMBL8723152 | 0.57 | CHEK1 (0.38) | CHEK1AURKADAPK3JAK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3284832-B1 | APTAMER WITH IMPROVED RATE OF DISSOCIATION, AND NON-COVALENT APTAMER-TARGET COMPLEX THEREOF | SOMALOGIC OPERATING CO INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20180369268-A1 | METHODS FOR IDENTIFYING INHIBITORS OF \"STIMULATOR OF INTERFERON GENE\"- DEPENDENT INTERFERON PRODUCTION | Aduro Biotech, Inc. (US) | 2018-12-27 | — | — | US | claimed |
| EP-3284832-A2 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES | Somalogic, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| EP-2933340-B1 | Aptamers with uridines and/or thymidines substituted at the 5-position with a benzyl group | SOMALOGIC INC (US) | 2017-09-06 | — | — | EP | claimed |
| WO-2017106740-A1 | METHODS FOR IDENTIFYING INHIBITORS OF \"STIMULATOR OF INTERFERON GENE\"-DEPENDENT INTERFERON PRODUCTION | Aduro Biotech, Inc. (US) | 2017-06-22 | — | — | WO | claimed |
| US-20170137819-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. | 2017-05-18 | — | — | US | claimed |
| EP-2933340-A1 | Chemically modified aptamers with improved off-rates | Somalogic, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| US-20150197753-A1 | Method for Generating Aptamers with Improved Off-Rates | SOMALOGIC, INC. | 2015-07-16 | — | — | US | claimed |
| US-8975388-B2 | Method for generating aptamers with improved off-rates | SOMALOGIC, INC. (US) | 2015-03-10 | — | — | US | claimed |
| US-8404830-B2 | Method for generating aptamers with improved off-rates | SOMALOGIC, INC. (US) | 2013-03-26 | — | — | US | claimed |
| EP-1019497-A1 | HAMMERHEAD RIBOZYMES WITH EXTENDED CLEAVAGE RULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | claimed |
| JP-2000501284-A | — | — | 2000-02-08 | — | — | JP | claimed |
| WO-1998058057-A9 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LAB INC (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1998058057-A1 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LABORATORIES, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| WO-1998058058-A1 | HAMMERHEAD RIBOZYMES WITH EXTENDED CLEAVAGE RULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0866865-A1 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | Vimrx Holdings, Ltd. (US) | 1998-09-30 | — | — | EP | claimed |
| WO-1997018312-A9 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | — | 1998-08-13 | — | — | WO | claimed |
| WO-1997018312-A1 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | VIMRX HOLDINGS, LTD. (US) | 1997-05-22 | — | — | WO | claimed |
| EP-0236935-A2 | Carboxylic purine nucleosides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-16 | — | — | EP | claimed |
| EP-0219838-A2 | Carbocyclic purine nucleosides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369268-A1 | METHODS FOR IDENTIFYING INHIBITORS OF \"STIMULATOR OF INTERFERON GENE\"- DEPENDENT INTERFERON PRODUCTION | STING1, CGAS, IRF3 | CHEK1 425/4885AURKA 4298/4885DAPK3 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.